Cyclacel Pharmaceuticals Files 8-K Report

TL;DR

Cyclacel Pharma filed an 8-K on 3/19/24, confirming HQ address and basic company info.

AI Summary

On March 19, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. The report confirms the company's incorporation in Delaware and provides its IRS Employer Identification Number as 91-1707622.

Why It Matters

This 8-K filing serves as an official update on the company's operational and financial status, providing key identifying information for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate information and does not contain significant new financial or operational developments.

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — Registrant
• March 19, 2024 (date) — Date of earliest event reported
• 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 (location) — Principal executive offices address
• Delaware (jurisdiction) — State of incorporation
• 91-1707622 (identifier) — IRS Employer Identification Number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma

Filing Documents

• tm249239d1_8k.htm (8-K) — 28KB
• tm249239d1_ex99-1.htm (EX-99.1) — 72KB
• image_003.jpg (GRAPHIC) — 32KB
• 0001104659-24-036148.txt ( ) — 368KB
• cycc-20240319.xsd (EX-101.SCH) — 3KB
• cycc-20240319_def.xml (EX-101.DEF) — 26KB
• cycc-20240319_lab.xml (EX-101.LAB) — 36KB
• cycc-20240319_pre.xml (EX-101.PRE) — 25KB
• tm249239d1_8k_htm.xml (XML) — 5KB

02

Item 2.02 Results of Operations and Financial Condition. The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the " Company "), dated March 19, 2024, announcing certain financial results for the fourth quarter and full year ended December 31, 2023. The Company will conduct a conference call to review its financial results on March 19, 2024, at 4:30 p.m., Eastern Time.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release announcing financial results for the fourth quarter and full year ended December 31, 2023, dated March 19, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: March 19, 2024

View Full Filing

View this 8-K filing on SEC EDGAR